Pharmaceutical Technology

SEPTEMBER 19, 2023

Pelican Technology has combined business with Primordial Genetics under a deal to create a private biotechnology company Primrose Bio.

Genetics 263

Genetics 263

Pharmaceutical Technology

SEPTEMBER 15, 2023

Cure Genetics has entered a partnership and licensing deal with Frametact to develop gene therapy for familial neurological ailments.

Genetics 246

Genetics Gene Gene Therapy Licensing 246

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 7, 2024

When research tells us that our grandparents’ diets can affect our health decades later, it can be hard to shake the feeling that genetics spells out the trajectory of our wellbeing. But how much of our health is actually determined by our genes, and what effect does our lifestyle have, for better or worse? Can […]

Genetics 245

Genetics Gene Research Clinical Trials 245

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 13, 2023

Now an international team of researchers has discovered a new genetic variant in people of African ancestries that appears to restrict HIV replication after an infection sets in. A tiny fraction of people are naturally resistant to HIV infections, and scientists want to understand why.

Genetics 246

Genetics Scientist Research Clinical Trials 246

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 21, 2022

Scientists have found an extremely subtle twist in the genetics of aging cells, one that seems to make them increasingly less functional as time goes on.

Genetics 239

Genetics Gene Scientist Research 239

XTalks

DECEMBER 18, 2024

CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens.

Genetics 116

Genetics Hormones Trials Drugs 116

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 18, 2024

Indian healthcare industry is of the view that emergence of genetic diagnostics will be a paradigm shift towards personalized medicine. Through the ever-evolving landscape of healthcare, the role of genetic diagnostics offers personalized insights and proactive solutions for disease management and prevention.

Genetics 189

Genetics Medicine Development Drugs 189

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 17, 2024

We are witnessing a revolution in healthcare, driven by advances in genetics, Omics, RNA and CRISPR gene-editing technology, to deliver precision and personalised medicine, said Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics. This holds the potential to cure genetic diseases that have plagued families for generations.

Genetic Disease 189

Genetic Disease Genetics Gene Editing Medicine 189

Bio Pharma Dive

DECEMBER 14, 2022

A four-year agreement between the companies comes with $170 million in cash and equity for Wave, which in recent years has dealt with clinical setbacks.

Genetics 321

Genetics Medicine 321

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 14, 2023

Indian healthcare looks at pharmacogenomics, the study of influence of genetic factors on drug response, in patient care as comprehensive genetic tests gain ground.

Genetics 188

Genetics Drugs Clinical Trials Clinical Trials 188

Bio Pharma Dive

DECEMBER 15, 2020

The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease.

Gene Therapy 306

Gene Therapy Genetics Medicine Gene 306

Bio Pharma Dive

JUNE 25, 2024

The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.

Medicine 286

Medicine Genetics RNA 286

Bio Pharma Dive

JANUARY 6, 2022

For $50 million, Lilly has secured rights to a technology that's meant to transport nucleic acid therapies in a way that's more targeted and better tolerated than other methods.

Genetics 300

Genetics 300

Bio Pharma Dive

JUNE 3, 2021

Study results disclosed ahead of ASCO could make Lynparza a standard "adjuvant" treatment for people with an inherited form of breast cancer — as long as they know they have it.

Genetics 356

Genetics Drugs 356

Bio Pharma Dive

FEBRUARY 12, 2021

The biotech set an average annual price of $450,000 for the first-of-its-kind drug, which treats a condition that affects about 1,300 people in the U.S.

FDA Approval 300

FDA Approval Genetics Drugs 300

Bio Pharma Dive

SEPTEMBER 18, 2020

Data confirming the company's drug Padcev can extend the lives of bladder cancer patients should strengthen its position with regulators, although Immunomedics is close behind with a competing treatment.

Genetics 296

Genetics Regulation Drugs 296

Pharma Times

AUGUST 9, 2024

The study revealed that 13% of patients have a genetic form of the neurological disease

Genetics 146

Genetics 146

Bio Pharma Dive

OCTOBER 9, 2024

The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.

Genetics 278

Genetics Medicine 278

Bio Pharma Dive

AUGUST 9, 2023

Third Rock-founded Decibel, which has shed much of its value since a 2021 IPO, expected to run out of money within a year.

Genetics 245

Genetics Medicine 245

Bio Pharma Dive

MAY 2, 2022

The partners increased the size and length of a large, ongoing study in transthyretin amyloidosis cardiomyopathy, a decision that has implications Alnylam Pharmaceuticals, which is testing two of its drugs against the disease.

Genetics 299

Genetics Trials Drugs 299

Bio Pharma Dive

JUNE 29, 2022

The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.

Genetics 255

Genetics Medicine Development 255

Pharmaceutical Technology

NOVEMBER 27, 2024

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease treatments.

Genetic Disease 130

Genetic Disease Genetics Licensing Licensing 130

Bio Pharma Dive

MARCH 18, 2025

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients have with therapies from Alnylam and Novo Nordisk.

Genetics 177

Genetics 177

Pharmaceutical Technology

OCTOBER 23, 2024

Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs).

Gene Therapy 130

Gene Therapy Genetics Gene Development 130

Bio Pharma Dive

OCTOBER 18, 2022

At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.

In-Vivo 359

In-Vivo Genetics 359

Bio Pharma Dive

APRIL 6, 2022

Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease.

Gene Therapy 344

Gene Therapy Gene Genetics Medicine 344

Pharmaceutical Technology

APRIL 22, 2024

Discover how Synlogic Inc's patented genetically engineered bacteria produce short-chain fatty acids to combat metabolic diseases. Learn more about this innovative treatment approach.

Genetic Engineering 130

Genetic Engineering Bacteria Engineer Genetics 130

Bio Pharma Dive

MARCH 10, 2025

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell by double digits.

Genetics 269

Genetics 269

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 301

Gene Editing Gene Genetics Medicine 301

pharmaphorum

AUGUST 6, 2024

Discover how Step Pharma is harnessing genetics and developing therapeutics targeting CTPS1 to advance cancer research and enhance clinical success. Learn more about their innovative approach.

Genetics 119

Genetics Research Development 119

Bio Pharma Dive

AUGUST 16, 2021

The FDA cleared Welireg, which Merck picked up in its $1 billion takeover of Peloton Therapeutics, to treat certain tumors associated with a rare genetic disease.

Genetic Disease 328

Genetic Disease Genetics Drugs 328

XTalks

OCTOBER 29, 2024

Genomic sequencing is a window into our genetic makeup. The GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, recently published in the Journal of the American Medical Association (JAMA) , highlights how adding genome sequencing to newborn screening could reshape early detection for rare genetic conditions.

Genome 95

Genome Genomics Genetics Life Science 95

Pharmaceutical Technology

APRIL 22, 2024

Enhance immunoglobulin diversity with AbCellera's patented method for isolating B cells from genetically modified mice. Discover a broader repertoire of antibodies with a recently granted patent.

Genetics 130

Genetics Antibody Production 130

Bio Pharma Dive

DECEMBER 12, 2023

Based on the work of MIT scientists, the well-funded startup is developing ways to insert large sizes of genetic material anywhere in the genome without damaging or breaking DNA.

Genome 328

Genome Genomics DNA Genetics 328

Bio Pharma Dive

JUNE 15, 2023

Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).

Gene Editing 316

Gene Editing Gene Genetics Medicine 316

Medical Xpress

DECEMBER 27, 2024

UT Southwestern Medical Center researchers have identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system.

Genetics 113

Genetics Medicine Research 113

Bio Pharma Dive

MARCH 1, 2023

At a time when many startups have struggled to gain cash, the biotech has raised another $135 million to back its research, a new twist on genetic medicine.

Genetics 311

Genetics Medicine Research 311